Yi-zhou Z. Jiang
No.270 Dong'an Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 186 publications
HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer.
Journal: Cell metabolism
Published: July 30, 2026
Current and future therapies for triple-negative breast cancer.
Journal: Journal of hematology & oncology
Published: May 04, 2026
Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 11, 2026
Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2-breast cancer: A randomized, phase 2 trial FASCINATE-N.
Journal: Cell reports. Medicine
Published: February 04, 2026
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: December 23, 2025
Integrated analysis reveals the impact of obesity on triple-negative breast cancer.
Journal: Cancer letters
Published: November 06, 2025
Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.
Journal: Signal transduction and targeted therapy
Published: October 19, 2025
NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2- Breast Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 26, 2025
Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer.
Journal: Genome medicine
Published: September 22, 2025
Last Updated: 09/26/2026